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Abstract
The methodological advancements made in the field of joint models are numerous. None the less,
the case of competing risks joint models have largely been neglected, especially from a practitioner’s
point of view. In the relevant works on competing risks joint models, the assumptions of Gaussian
linear longitudinal series and proportional cause-specific hazard functions, amongst others, have remained
unchallenged. In this paper, we provide a framework based on R-INLA to apply competing risks joint
models in a unifying way such that non-Gaussian longitudinal data, spatial structures, time dependent
splines and various latent association structures, to mention a few, are all embraced in our approach.
Our motivation stems from the SANAD trial which exhibits non-linear longitudinal trajectories and
competing risks for failure of treatment. We also present a discrete competing risks joint model for
longitudinal count data as well as a spatial competing risks joint model, as specific examples.
1 Introduction
Time to event data is observed in its simplest form, as the time when a particular event happens or when
the monitoring process halts (censoring time). A competing risks model (Hoel, 1972; Moeschberger and
David, 1971; Altshuler, 1970) arises in the case where patients are at risk for one of multiple events,
i.e. multiple mutually exclusive outcomes. The occurence of an event precludes all other events, so that
each observational unit is at risk for each of the C events, until one event occurs. After this, the risk
of the other events are all zero. There are mainly two modeling approaches in this respect, the subdis-
tribution (Fine and Gray, 1999) and cause-specific hazards approaches (Prentice et al., 1978). In the
subdistribution approach the data enters the model through a predictor term in each of the cumulative
incidence functions, the cumulative probability of experiencing the specific event. On the other hand,
the cause-specific approach incorporates the data through a predictor term for each of the cause-specific
hazard functions. Debates surrounding the choice between the two approaches are still ongoing, with
the consensus being that the cause-specific hazards approach should be chosen for causal inference of
covariate effects.
In most situations, additional data is available in the form of repeated measurements over time con-
stituting a longitudinal data set. The joint modeling of the competing risks data and the longitudinal
data (Hu et al., 2009; Elashoff et al., 2007) is often necessary since the missing longitudinal observations
are not missing at random but rather due to the occurrence of one of the competing events. Ignoring this
phenomena, will bias the longitudinal estimates. If the treatment efficacy is being evaluated, then the
joint modeling enables us to evaluate the treatment effect in both endpoints simultaneously. Unobserved
heterogeneity in the individuals due to some latent effect over time can be successfully accommodated
through the joint modeling.
Computational frameworks for competing risks, have been developed in recent years such as the CFC
package (Sharabiani and Mahani, 2017) and the cmprsk package (Gray, 2014). The existence of these
frameworks is essential for catalyzing the use of competing risks models in practice.
For joint modeling of competing risks and longitudinal data the R package joineR (Philipson et al., 2018)
can be used. This package implements the model developed by Williamson et al. (2008). This model is a
cause-specific Cox proportional hazards regression model (for two competing events) and a linear mixed
effects model with an assumed latent Gaussian association process. An accelerated failure time (AFT)
model, a non-Gaussian distribution for the longitudinal model component or spatial data thus excludes
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the use of joineR.
Practitioners depend largely on the availability of wieldy computational frameworks to ease the compu-
tational burden of implementing such joint models. On the flip side, too many different developments
could confuse the potential users and exacerbate the hesitation to applying competing risks models. This
is especially true when more complex models are needed and new packages are developed for each addi-
tional complexity. This is cumbersome for users since many different packages should be familiarized for
common use. The exigency for a more cohesive approach to competing risks joint models is clear. We
believe that we address this deficiency in this paper.
To achieve our aim, of presenting a cohesive computational framework for competing risks joint models,
we are spurred to characterize competing risks models within the class of latent Gaussian models. This
characterization enables us to use the integrated nested Laplace approximation (INLA) method proposed
by Rue et al. (2009). Our rationale for this endeavor is the computational efficiency and ability to incor-
porate various modeling elements available in the accompanying R-INLA package (Rue et al., 2011). The
INLA framework has been used in various fields of application since its inception. In survival analysis,
Martino et al. (2011) provided the details for basic survival models and A´lvaro-Meca et al. (2013) pre-
sented an approach for competing risks models using R-INLA, while Van Niekerk et al. (2019) presented
the case of joint survival longitudinal modeling. Competing risks joint models with frailties (Martino
et al., 2011), spatial structures (Bakka et al., 2018) and non-linear covariate effects (Lindgren and Rue,
2008) with non-Gaussian longitudinal submodels are all natural possibilities within our framework.
In the SANAD trial (Marson et al., 2007), the aim was to evaluate the efficacy of various treatments
for seizure control in patients with epilepsy. Two treatment failure types, unacceptable adverse effects
(UAE) and inadequate seizure control (ISC) were considered as competing events. From exploratory data
analysis the non-linear mean trajectory of the titration dosage over time for the two different treatments
is clear and also noted by Williamson et al. (2008). A piecewise linear model with two different slopes
(with the changepoint at time 500) was used by Williamson et al. (2008) as an attempt to properly
model this phenomena. We, however, propose a fully nonparametric spline component to capture this
non-linear behavior over time in the form of a random walk order two model. This type of non-linear
competing risks model can be formulated as a latent Gaussian model which can then be fitted using the
established R-INLA framework for accurate and efficient computation. This endeavor resulted in better
results for the SANAD trial as well as the development of a class of latent Gaussian competing risks
joint models for various other realistic data situations such as longitudinal count data, spatial data and
correlated competing risks to name a few.
In Section 2 we present an introduction and necessary details of competing risks joint models in general
which is then formulated as latent Gaussian models in Section 3. We also provide two specific examples of
competing risks joint models which might arise in practice to give the reader an intuition for the proposed
methodology. We apply the proposed method to the SANAD trial in Section 4 and a simulation study
for a discrete competing risks joint model (longitudinal count data) is presented in Section 5. Finally, we
conclude with a discussion in Section 6 on the proposed method and some exciting possibilities thereof.
2 Joint models for competing risks and longitudinal data
The applications of joint models have increased over the last few years. Essentially, a joint model is a
statistical method to model two or more dependent endpoints/responses. Joint models in spatial statistics
are known as coregionalization models (Schmidt and Gelfand, 2003; Krainski et al., 2018) where there
is dependency between multiple spatial fields. In survival analysis, the use of joint models to infer joint
survival longitudinal models is very popular. In these cases, joint modeling is fundamentally correct
since the time to event process and the longitudinal data per individual is inherently dependent, since it
is governed by the same biological process. Although joint models are popular in survival analysis with
one event of interest, the potential for their application in more complicated survival models has yet
to be explored. In this paper, we focus on competing risks joint models with various realistic features
like mutiple events of interest, spatial random effects and non-linear longitudinal trajectores. To this
end, we present cause-specific competing risks joint models, with proportional or non-proportional cause-
specific hazard functions and non-Gaussian or Gaussian longitudinal series as latent Gaussian models.
This venture allows the use of the fast and accurate INLA methodology Rue et al. (2009) for Bayesian
inference of the model.
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2.1 Cause-specific competing risks joint model
The competing risks joint model is used to do inference for the biological process that underpins the
longitudinal and competing risks data. For simplicity we assume C competing risks and one longitudinal
marker in this section, even though our approach can be used for various longitudinal markers.
For the longitudinal marker y, we formulate a linear predictor ηL and vector of hyperparameters, θL for
N individuals with a total of NL = N1 + N2 + ... + NN observations. Note that we do not make any
distributional assumptions, hence denote the likelihood of y as
piL(y|ηL, θL) =
NL∏
l=1
piL(yl|ηLl , θL). (1)
As before, denote the cause-specific hazard function for cause j, j = 1, ..., C at time t as
hj(t|ηj , θj),
where ηj is the linear predictor. The vector of hyperparameters θj is associated with the cause-specific
hazard function, for example the baseline hazard parameters for the Cox proportional hazard model or
the shape parameter of the Weibull accelerated failure time (AFT) model. The likelihood function for
the observed event times t = {t1, ..., tN} with event indicators d = {dij}, i = 1, ..., N, j = 1, ..., C is
piS(t|η,θ) =
N∏
i=1
C∏
j=1
hij(ti|ηji , θj)dij exp
(
−
∫ ti
0
hij(u|ηji , θj)du
)
, (2)
where dij is an indicator if individual i died from cause j. The linear predictors, η
j and ηL, have an
additive structure of fixed and random effects as follows:
η = βZ +
K∑
k=1
fk(uik)
where fk(uik) is the k
th random effect of covariate uik for individual i. This formulation allows us to in-
clude spatial fields, spline components and frailties within our approach to joint competing risks models.
The form of the linear predictor facilitates the contextualization of this joint competing risks model as a
latent Gaussian model.
3 Competing risks joint models as Latent Gaussian models
In this section we briefly present the details of latent Gaussian models (LGMs) and the integrated
nested Laplace approximations (INLA) method for approximate Bayesian inference. If we can formulate
competing risks joint models as LGMs and consequently use INLA for the inference, then we can fit these
types of models very efficiently and with complex modeling components.
3.1 Latent Gaussian models and the integrated nested Laplace approx-
imations method
Latent Gaussian models is a specific subset of hierarchical Bayesian additive models. This class comprises
of well-known models such as mixed models, temporal and spatial models amongst many others. An
LGM is defined as a model having a specific hierarchical structure, as follows:
1. The observed responses, {yi}, are conditionally independent based on the likelihood hyperparam-
eters θ1 and the linear predictors {ηi}. (Note that non-Gaussian distributions as well as multiple
distributions for subsets of the responses, can be assumed.)
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2. The linear predictor is formulated as follows:
ηi = β0 + βX +
K∑
k=1
fk(uik) + i (3)
where β represent the linear fixed effects of the covariates X ,  is the unstructured random effects
and the {fk(.)}’s represent unknown (non-linear) functions of the covariates u. The unknown
functions {fk(.)}’s, also known as structured random effects, include spline models, spatial effects,
temporal effects, non-separable spatio-temporal effects, frailties, subject or group-specific intercepts
and slopes etc.
3. The latent field X is formed from the structured additive predictor as {β0,β, {fk(.)}, η} with a
multivariate Gaussian prior such that the latent field forms a Gaussian Markov random field with
sparse precision matrix Q(θ2), i.e. X ∼ N(0,Q−1(θ2)).
4. A prior (possibly non-Gaussian), pi(θ) can then be formulated for the set of hyperparameters θ =
(θ1, θ2).
From this hierarchical Bayesian formulation the joint posterior distribution is then given by:
pi(X , θ) ∝ pi(θ)pi(X |θ)
∏
i
pi(yi|X , θ) (4)
Within this framework the joint posterior density (4) and subsequently the marginal posterior densities,
pi(Xi|y), i = 1...n and pi(θ|y) can be efficiently and accurately calculated using the INLA methodology
developed by Rue et al. (2009), without using Gibbs sampling.
3.2 Competing risks joint models as LGMs
In this section we show that most competing risks joint models are indeed LGMs and can therefore be
defined as one model. This enables the use of the INLA methodology for many different competing risks
joint models, for example discrete competing risks joint models, spatial competing risks joint models,
non-linear competing risks joint models, correlated competing risks joint models etc.
Consider the case with C competing risks, N individuals with time to event observations t and event
variable d, and M series’ of longitudinal observations each of size Nl, l = 1, ...,M . Let di, i = 1, ..., C be
a vector of indicators if the event type is i.
Now define the stacked response list ystacked = {y1, y2, ..., yM , (t1, d1), (t2, d2), ..., (tC , dC)}. Also de-
fine the stacked linear predictor ηstacked = {ηL1 , ηL2 , ..., ηLM , η1, η2, ..., ηC , } as in (1) and (2) where each
component is of the form (3). For each component we define two vectors of hyperparameters, θ1
for the hyperparameters from the likelihood (like a precision parameter if a Gaussian distribution is
assumed, or the shape parameter for a Weibull model etc.) and θ2 for the hyperparameters from
the random effects in the linear predictor (like a range parameter for a spatial effect, or a preci-
sion parameter for a spline effect etc.), such that the stacked vector of hyperparameters is θstacked =
{θL1,1, θL2,1, θL1,2, θL2,2, ..., θL1,M , θL2,M , θ1,1, θ2,1, θ1,2, θ2,2, ..., θ1,C , θ2,C}. The latent field is then defined as
X = {β stacked, ηstacked, {f (.)}stacked}, and we assume a multivariate Gaussian prior for X .
From this construction the cause-specific competing risks joint model (in general, with various ran-
dom effects like spatial fields, spline effects, correlated models etc.) is an LGM and the joint posterior
distribution of the latent field and the hyperparameters is
pi(X , θstacked) ∝ pi(θstacked)pi(X |θstacked)
length(ystacked)∏
i=1
pi(yi|X , θstacked).
Since this proposition is abstract we provide some specific examples of relevant competing risks joint
models in the next section.
3.3 Specific examples
Next we present some specific (non-exhaustive) examples of competing risks joint models that fit in this
framework.
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3.3.1 Example 1. Poisson competing risks random-effects joint model
Suppose that the longitudinal observations, yi(t) follow a Poisson distribution with mean λi(t), i.e.,
yi(t) ∼ Poisson(λi(t)) with λi(t) = exp(ηLi (t)). Also assume three competing causes and a Weibull
model for all the cause-specific hazard functions with shape parameters α1, α2, α3, i.e. for observed time
ti with event indicators di = {di1, di2, di3}, hij(t) = αj(γij)αj tαj−1 with γij = exp(η(j)i ), j = 1, 2, 3.
Now define the associated linear predictors as follows:
ηL(t) = βLXL(t) + v +wt (5)
η(1)(t) = β (1)X (1)(t) + γ(1)v + κ(1)wt
η(2)(t) = β (2)X (2)(t) + γ(2)v + κ(2)wt
η(3)(t) = β (3)X (3)(t) + γ(3)v + κ(3)wt,
where
[
vi
wi
]
∼ N
([
0
0
]
,
[
τ−1v ρ
ρ τ−1w
])
. Note that we do not enforce the same scaling parameter for the
two random effects but accommodate for different scalings of the random intercept and the random slope.
Now define θ = {α1, α2, α3, τ−1v , τ−1w , ρ} as the vector of hyperparameters. Define the latent field
X = {βL,β (1),β (2),β (3), ηL, η(1), η(2), η(3), v,w},
then this competing risks joint model is an LGM following Section 3.
3.3.2 Example 2. Spatial competing risks joint model with smoothed longitudinal
predictor as the association term and unknown non-linear time trend
Suppose that the longitudinal observations, yi follow a Gaussian distribution with mean µi and precision
parameter τ , i.e., yi ∼ N(µi, τ−1) with µi = ηLi (s, t) with t a time index and s a space index. Also
assume three competing causes and an exponential model for all the cause-specific hazard functions i.e.
for observed time ti with event indicators di = {di1, di2, di3}, hij(t) = λij with λij = exp(η(j)i ), j = 1, 2, 3.
Now define the associated linear predictors as follows:
ηL(s, t) = βLXL(t) + v + f(t) + u(s) (6)
η(1)(s, t) = β (1)X (1)(t) + γ(1)ηL(s, t)
η(2)(s, t) = β (2)X (2)(t) + γ(2)ηL(s, t)
η(3)(s, t) = β (3)X (3)(t) + γ(3)ηL(s, t),
where f(t) is an unknown non-linear function of time (i.e. a spline component) with hyperparameters
θtime and u(s) is a spatial field (eg. Besag (***) or BYM (**) models for discrete regions or SPDE (eg.
Matern) (***) model for continuous space) with hyperparameters θspace. Now each cause-specific hazard
function is associated with the longitudinal process through its own scaling γ(j).
Now define θ = {θtime, θspace, τ} as the vector of hyperparameters. Define the latent field
X = {βL,β (1),β (2),β (3), ηL, η(1), η(2), η(3), f (.),u(.)},
then this spatial competing risks joint model is an LGM following Section 3.
4 Application - SANAD trial
The SANAD trial (Marson et al., 2007) was a randomized trial study to investigate the effect of seizure
control drugs in patient with epilepsy for whom carbamazepine (CBZ) was considered the standard
treatment protocol. The patients were randomly assigned to CBZ, lamotrigine (LTG), gabapentin,
oxcarbazepine and topiramate. In the main analysis, LTG appeared to be superior to CBZ but since
then various criticisms regarding this finding have risen, mainly due to the difference in titration speed
and therefore the dosage. In Williamson et al. (2008) this data was analyzed using a competing risks
random-effects joint model with a changepoint at time t = 500. In Figure 4 the mean trajectories for
the two treatment groups CBZ and LTG are presented. It is clear that the mean trajectories are firstly
different between the two treatments and secondly, the changepoint at t = 500 seems quite subjective
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since for CBZ the trajectory does not seems to have a constant linear trend after t = 500. We therefore
include a spline component in the form of a random walk order two model for the dosage trajectory over
time. Also, we do not enforce equal scaling for the random intercepts and slopes.
Figure 1: Mean trajectories for CBZ and LTG treatment groups
4.1 Bayesian competing risks joint model
We propose the following competing risks joint model with non-linear longitudinal trajectories for the
SANAD trial data,
ηL(t) = β0 + β1CBZ + CBZfCBZ(t) + LTGfLTG(t) (7)
η(UAE)(s) = β0 + β
(1)
1 CBZ + γ1η
L(s)
η(ISC)(s) = β0 + β
(2)
1 CBZ + γ2η
L(s),
where fCBZ is a random walk order two model (Lindgren and Rue, 2008) with hyperparameter τfCBZ on
the interaction of the time and CBZ, the CBZ treatment indicator, and similarly for LTG. We assume
a Gaussian longitudinal distribution with noise precision τL, and Weibull models for the cause-specific
hazard functions with hyperparameters αUAE, αISC. The priors for the latent field are all Gaussian i.e.,
β0 ∼ N(0, τ−1β0 ), γ1 ∼ N(0, τ−1γ1 ), γ2 ∼ N(0, τ−1γ2 ),
with penalizing complexity priors (Simpson et al., 2017) for most of the hyperparameters, such that
τ−0.5L ∼ Exp(λL), τ−0.5β0 ∼ Exp(λβ0), τ−0.5γ1 ∼ Exp(λγ1),
τ−0.5γ2 ∼ Exp(λγ2), τ−0.5fCBZ ∼ Exp(λCBZ), τ
−0.5
fLTG
∼ Exp(λCBZ),
10 ln(αUAE) ∼ N(0, τ−1UAE), 10 ln(αISC) ∼ N(0, τ−1ISC)
such that the user-defined parameter λ[.] is defined through the probability P (τ
−0.5
[.] > 1), as an example
P (τ−0.5[.] > 1) = 0.01 produces λ[.] = ln(0.01). Note that the exponential prior on σ[.] = τ
−0.5
[.] translates
to a Gumbel type 2 prior on τ[.]. The motivation for employing penalizing complexity priors for the
precision hyperparameters are founded in the fact that the usual priors for the variance components, i.e.
independent inverse-gamma priors as in Huang et al. (2018), overfits in the sense that it cannot contract
to the simpler model in which the respective model component has trivial variance. This is especially
important in the case of joint models since the effect of overfitting is exacerbated by the influence of the
shared random effect on all the linear predictors.
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4.2 Results
The estimated mean dosage trajectories for the two treatements, CBZ and LTG, on a log scale is presented
in Figure 4.2. The effect of the joint model on the longitudinal trajectories is clear. The dropout process
affects the longitudinal trajectories in a meaningful way.
Figure 2: Mean estimated dosage trajectories for the CBZ and LTG treatment groups
The estimated competing risks joint model is:
η̂L(t) = 2.438(2.319; 2.556) + 0.305(0.145; 0.465)CBZ + CBZfCBZ(t) + LTGfLTG(t)
η̂(UAE)(s) = 2.438(2.319; 2.556)− 0.726(−1.104;−0.371)CBZ− 1.1(−1.192;−1.02)ηL(s)
η̂(ISC)(s) = 2.438(2.319; 2.556)− 0.11(−0.406; 0.175)CBZ− 0.998(−1.087;−0.928)ηL(s),
with τfCBZ = 14.879, τfLTG = 7.055, αUAE = 0.84(0.05; 0.915) and αISC = 1.21(1.19; 1.33).
The negative association between the cause-specific hazard functions of UAE and ISC, repsectively,
and the smoothed dosage level should be interpreted with the shape parameters, αUAE and αISC of the
weibull models. For UAE, the estimated shape parameter is significantly smaller than 1 which implies
that as the dose increase over time as captured by η̂L(t) the linear predictor η̂(UAE)(s) will decrease
due to the negative association and even more so for treatment CBZ. The decreased η̂(UAE)(s) together
with αUAE = 0.84 leads to the conclusion that the hazard of UAE is lower for LTG than for CBZ, and
increasing over time since higher doses correspond to larger times. The converse is true for the hazard of
ISC since αISC is significantly larger than 1. Due to the insignificant effect of treatment on the hazard
of ISC, the two treatments under consideration provide similar seizure control.
Our findings are thus consistent with those of Williamson et al. (2008) with the added advantage of
the flexible estimated mean longitudinal trajectories for the two treatment dosages.
5 Simulation study - Discrete competing risks random-
effects joint model
In this section we simulate longitudinal count data as well as time to event data with three competing
risks (Causes 1, 2 and 3). We also included a non-linear time component in the longitudinal trajectory.
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The data is simulated from a competing risks joint random-effects model with a random intercept (similar
to (6)), such that for N individuals, each with Ni, i = 1, ..., N longitudinal counts and time to event ti
with event indicator di ∈ {0, 1, 2, 3} the model is
yi(t) ∼ Poisson(exp(t1.2 + ui))
h1(t) = exp(0.3ui + 0.01Age)
h2(t) = exp(−0.1ui + 0.015Age)
h3(t) = exp(0.2ui + 0.0003Age),
with Age a discrete explanatory variable within the range (15; 75) and ui ∼ N(0, 1) is a random intercept
which associates the longitudinal series with the cause-specific hazard functions, hj(t), j = 1, 2, 3. Note
that we also include a non-linear trend in the longitudinal trajectory, t1.2. In the simulation setup, we
induce a negative association between the hazard of event 2 and the longitudional series, whereas the
hazard of events 1 and 3 are positively correlated with the longitudinal series. From the above, the
hazard functions are constant over time and an exponential distribution is thus implied.
In Figure 3 the longitudinal series and the mean estimated trajectory from a random walk order two
model with precision τr is presented. The results are presented in Table 1 and it is clear that this
Figure 3: Simulated longitudinal data and estimated mean trajectory
challenging model is recovered well.
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Parameter True value Estimate 95% credible interval
σu 1 1.017 (0.925; 1.114)
β1 0.01 0.012 (0.005; 0.018)
β2 0.015 0.052 (0.009; 0.019)
β3 0.0003 0.0001 (−0.003; 0.005)
γ1 0.3 0.285 (0.192; 0.369)
γ2 −0.1 −0.108 (−0.206;−0.011)
γ3 0.2 0.208 (0.062; 0.352)
τr . 28.513 (11.709; 116.878)
Table 1: Estimates from the discrete competing risks joint model using R-INLA
6 Discussion
Here we presented a general method to apply a wide class of competing risks joint models using the
R-INLA framework. The main stimulus for this research was the necessity for a proper non-linear com-
peting risks joint model as motivated from the SANAD trial. Although we addressed this issue, we also
developed a class of latent Gaussian competing risks joint models which enables the practitioner to use
our method for various realistic situations which demands different types of competing risks joint models.
We presented the details of two specific realistic situations, one being a competing risks model with three
competing events and one longitudinal series of count data, the other a spatial competing risks joint
model. The application of the non-linear competing risks joint model to the SANAD trial proved fruitful
as this model properly captures the non-linear trajectory.
The possibility of a non-linear competing risks joint model based on a random walk order two model
emerged through the R-INLA framework. The INLA methodology (Rue et al., 2009) has been proved
to be a very efficient and popular computational platform for Bayesian models. The use of the R-INLA
framework necessitated the formulation of the proposed model as a latent Gaussian model, which in turn
facilitated the formulation of various other competing risks joint models that could arise in practical
situations, such as multiple longitudinal series, discrete longitudinal distributions, spatial models and
frailty models to name but a few.
The possibilities of realistic competing risks joint models that can be inferred through the proposed
methodology is vast and exciting. We only presented a selected few which we deemed interesting and
applicable. A thorough presentation of all the possibilities is not possible in this paper but we believe that
the general method presented herein catalyzes future research, especially different instances of competing
risks joint models motivated from a modeling perspective.
Code appendix
#Competing r i s k s s imulated example
N=1000 #number o f p a t i e n t s
N i=round ( r u n i f (N, min=10,max=15)) #Number o f l o n g i t u d i n a l ob s e rva t i on s per
person
#Generate time−dependent exponent i a l event t imes with i i d shared random
e f f e c t s term
#Surv iva l component
u i=1+rnorm (N, mean=0, sd=1) #i i d random e f f e c t
c o e f f =0.5 #share parameter
lambda=exp ( c o e f f ∗ u i )
s i=rexp (N, ra t e=lambda ) #exponent i a l s u r v i v a l t imes
#l i b r a r y ( purrr )
#c i=r b e r n o u l l i (N, p=0.9)# censo r ing
c i=rep (1 ,N) #no censo r ing
age=round ( r u n i f (N, 1 5 , 7 5 ) )
eta1 =0.3∗ u i +0.01∗ age
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eta2 =−0.1∗ u i +0.02∗ age
eta3 =0.2∗ u i +0.0003∗ age
lambda1=exp ( eta1 )
lambda2=exp ( eta2 )
lambda3=exp ( eta3 )
IDs=1:N
time1=rexp (n=N, ra t e=lambda1 )
Cause=rbinom (n=N, 3 , 0 . 6 )
time=rep (NA,N)
f o r ( i in 1 :N)
{ i f ( Cause [ i ]==1) { time [ i ]= rexp (n=1, ra t e=lambda1 [ i ] ) }
i f ( Cause [ i ]==2) { time [ i ]= rexp (n=1, ra t e=lambda2 [ i ] ) }
i f ( Cause [ i ]==3) { time [ i ]= rexp (n=1, ra t e=lambda3 [ i ] ) }
i f ( Cause [ i ]==0) { time [ i ]= rexp (n=1, ra t e =1)}
}
dataS<−data . frame ( ID=IDs ,C=Cause , Time=time , Age=age )
data1<−dataS
dataE1<−data1
dataE1$event<−dataE1$C
dataE1$event [ dataE1$event !=1]<−0
dataE2<−data1
dataE2$event<−dataE2$C
dataE2$event [ dataE2$event !=2]<−0
dataE2$event<−dataE2$event /2
dataE3<−data1
dataE3$event<−dataE3$C
dataE3$event [ dataE3$event !=3]<−0
dataE3$event<−dataE3$event /3
#Long i tud ina l component
t=rep (NA, sum( N i ) )
ID=rep (NA, sum( N i ) )
a=rep (NA, sum( N i ) )
a g e i=rep (NA, sum( N i ) )
t [ 1 : N i [ 1 ] ] = r u n i f ( N i [ 1 ] , min=0,max=s i [ 1 ] ) # obse rvat i on t imes
ID [ 1 : N i [ 1 ] ] = 1
a [ 1 : N i [ 1 ] ] = u i [ 1 ]
a g e i [ 1 : N i [ 1 ] ] = age [ 1 ]
f o r ( i in 2 :N){
t [ ( sum( N i [ 1 : ( i −1) ] )+1) : ( sum( N i [ 1 : ( i −1)])+ N i [ i ] ) ]= r u n i f ( N i [ i ] ,
min=0,max=s i [ i ] )
#obse rvat i on t imes
ID [ ( sum( N i [ 1 : ( i −1) ] )+1) : ( sum( N i [ 1 : ( i −1)])+ N i [ i ] ) ]= i #person ID
a [ ( sum( N i [ 1 : ( i −1) ] )+1) : ( sum( N i [ 1 : ( i −1)])+ N i [ i ] ) ]= u i [ i ]
#i i d random e f f e c t
a g e i [ ( sum( N i [ 1 : ( i −1) ] )+1) : ( sum( N i [ 1 : ( i −1)])+ N i [ i ] ) ]= age [ i ]
#i i d random e f f e c t
}
y=r p o i s (n=sum( N i ) , lambda=(exp ( t ˆ(1.2)+ a ) ) ) #l o n g i t u d i n a l re sponse with N i [ i ]
ob s e rva t i on s per person and a t ˆ2 trend
p lo t ( t , y , pch=1, cex =0.3) #view l o n g i t u d i o n a l data
#INLA on sim data
dataL<−data . frame (Time=t , Age=age i ,Y=y , ID=ID)
nL<−nrow ( dataL )
nS<−nrow ( dataS )
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f i x e d . e f f<−data . frame (mu=as . f a c t o r ( c ( rep (1 ,nL ) , rep (2 , nS ) , rep (3 , nS ) ,
rep (4 , nS ) ) ) ,
ageL=c ( dataL$Age , rep (0 , nS ) , rep (0 , nS ) , rep (0 , nS ) ) ,
age1=c ( rep (0 ,nL ) , dataS$Age , rep (0 , nS ) , rep (0 , nS ) ) ,
age2=c ( rep (0 ,nL ) , rep (0 , nS ) , dataS$Age , rep (0 , nS ) ) ,
age3=c ( rep (0 ,nL ) , rep (0 , nS ) , rep (0 , nS ) , dataS$Age ) ,
Ltime=c ( dataL$Time , rep (0 , nS ) , rep (0 , nS ) , rep (0 , nS ) ) ,
C1time=c ( rep (0 ,nL ) , dataS$Time , rep (0 , nS ) , rep (0 , nS ) ) ,
C2time=c ( rep (0 ,nL ) , rep (0 , nS ) , dataS$Time , rep (0 , nS ) ) ,
C3time=c ( rep (0 ,nL ) , rep (0 , nS ) , rep (0 , nS ) , dataS$Time ) )
random . e f f<− l i s t ( timeL=c ( dataL$Time , rep (NA, nS ) , rep (NA, nS ) , rep (NA, nS ) ) ,
Lr1=c ( dataL$ID , rep (NA, nS ) , rep (NA, nS ) , rep (NA, nS ) ) ,
Lr2=c ( dataL$ID , rep (NA, nS ) , rep (NA, nS ) , rep (NA, nS ) ) ,
C1r1=c ( rep (NA, nL ) , dataS$ID , rep (NA, nS ) , rep (NA, nS ) ) ,
C1r2=c ( rep (NA, nL ) , dataS$ID , rep (NA, nS ) , rep (NA, nS ) ) ,
C2r1=c ( rep (NA, nL ) , rep (NA, nS ) , dataS$ID , rep (NA, nS ) ) ,
C2r2=c ( rep (NA, nL ) , rep (NA, nS ) , dataS$ID , rep (NA, nS ) ) ,
C3r1=c ( rep (NA, nL ) , rep (NA, nS ) , rep (NA, nS ) , dataS$ID ) ,
C3r2=c ( rep (NA, nL ) , rep (NA, nS ) , rep (NA, nS ) , dataS$ID ) )
jo in tdata<−c ( f i x e d . e f f , random . e f f )
y . long <− c ( dataL$Y , rep (NA, nS ) , rep (NA, nS ) , rep (NA, nS ) )
y . survC1 <− i n l a . surv ( time = c ( rep (NA, nL ) , dataS$Time , rep (NA, nS ) , rep (NA, nS ) ) ,
event = c ( rep (NA, nL ) , dataE1$event , rep (NA, nS ) , rep (NA, nS ) ) )
y . survC2 <− i n l a . surv ( time = c ( rep (NA, nL ) , rep (NA, nS ) , dataS$Time ,
rep (NA, nS ) ) ,
event = c ( rep (NA, nL ) , rep (NA, nS ) , dataE2$event , rep (NA, nS ) ) )
y . survC3 <− i n l a . surv ( time = c ( rep (NA, nL ) , rep (NA, nS ) , rep (NA, nS ) ,
dataS$Time ) ,
event = c ( rep (NA, nL ) , rep (NA, nS ) , rep (NA, nS ) , dataE3$event ) )
y . j o i n t<− l i s t ( y . long , y . survC1 , y . survC2 , y . survC3 )
jo intdata$Y=y . j o i n t
#Model f i t
formula . model=Y˜−1+mu+age1+age2+age3+
f ( i n l a . group ( timeL , n=50) , model=”rw2 ” , s c a l e . model = TRUE, hyper = l i s t ( prec =
l i s t ( p r i o r=”pc . prec ” , param=c (1 , 0 . 01 ) ) ) )+
f ( Lr1 , model=” i i d ”)+
f ( C1r1 , copy=”Lr1 ” , f i x e d=FALSE)+
f ( C2r1 , copy=”Lr1 ” , f i x e d=FALSE)+
f ( C3r1 , copy=”Lr1 ” , f i x e d=FALSE)
Jointmodel= i n l a ( formula . model , f ami ly = c (” po i s son ” ,” exponent i a l su rv ” ,” exponent i a l su rv ” ,
” exponent i a l su rv ”) ,
data = jo in tdata , verbose=TRUE)
summary( Jointmodel )
p l o t ( t , y , pch=1, cex =0.3 , ylab=”Count ” , xlab=”Time”) #view l o n g i t u d i o n a l data
l i n e s ( Jointmodel$summary . random$ ‘ i n l a . group ( timeL , n = 5 0 ) ‘ [ , 1 ] , exp ( Jointmodel$summary . random$ ‘ i n l a . group ( timeL , n = 5 0 ) ‘ [ , 2 ] ) ,
c o l=”blue ” , lwd=2)
##########################################################
#SANAD − e p i l e p t i c
l i b r a r y ( jo ineR )
11
l i b r a r y (INLA)
mTime=max(max( e p i l e p t i c $ t i m e ) ,max( e p i l e p t i c $ w i t h . time ) )
e p i l e p t i c $ t i m e<−e p i l e p t i c $ t i m e /mTime
e p i l e p t i c $ w i t h . time <−e p i l e p t i c $ w i t h . time /mTime
e p i l e p t i c $ i n t e r a c t i o n <− with ( e p i l e p t i c , time ∗ ( t r e a t == ”LTG”))
e p i l e p t i c $ i n t e r a c t i o n 2 <− with ( e p i l e p t i c , time ∗ ( t r e a t == ”CBZ”))
e p i l e p t i c $ i n t e r a c t i o n [ e p i l e p t i c $ i n t e r a c t i o n==0]<−NA
e p i l e p t i c $ i n t e r a c t i o n 2 [ e p i l e p t i c $ i n t e r a c t i o n 2==0]<−NA
data1<−e p i l e p t i c
dataL<−data . frame ( ID=data1$id , LDose=log ( data1$dose +0.1) ,Time=data1$time ,
TimeSp=data1$time , Age=data1$age , Gender=data1$gender ,LD=data1$ learn . d is ,
Treatment=data1$treat , InteractionLTG=data1$ in t e rac t i on , InteractionCBZ=
data1$ in t e rac t i on2 , l i s t (V=data1$id ,W=data1$id ) , Dose=data1$dose )
dataS<−data . frame ( ID=data1$id , Time=as . numeric ( data1$with . time ) , Status=
data1$with . s tatus2 , StatusISC=data1$with . s t a t u s . i s c , StatusUAE=
data1$with . s t a t u s . uae , Age=data1$age , Gender=data1$gender ,LD=data1$ learn . d is ,
Treatment=data1$t rea t )
dataS<−subset ( dataS , ! dup l i ca t ed ( dataS$ID ) )
summary( dataL )
summary( dataS )
#V i s u a l i z e
p l o t ( dataL$Time [ dataL$ID==42] , dataL$Dose [ dataL$ID==42] , type=”n” ,
xlim=c ( 0 , 1 ) , yl im=c ( 0 , 1 0 ) )
f o r ( i in unique ( dataL$ID )){
l i n e s ( dataL$Time [ dataL$ID==i ] , dataL$Dose [ dataL$ID==i ] , c o l=i )
}
dataLCBZ=dataL [ dataL$Treatment==”CBZ” , ]
dataLLTG=dataL [ dataL$Treatment==”LTG” , ]
#Mean t r a j e c t o r i e s
modCBZ<−i n l a ( formula=dataLCBZ$Dose˜ f ( i n l a . group (dataLCBZ$Time , n=50) ,
model=”rw2 ” , s c a l e . model = TRUE, hyper = l i s t ( prec = l i s t ( p r i o r=”pc . prec ” ,
param=c (1 , 0 . 0 1 ) ) ) ) , data=dataLCBZ , fami ly=”gauss ian ” , c o n t r o l . compute=
l i s t ( d i c=TRUE, c o n f i g=TRUE) )
modLTG<−i n l a ( formula=dataLLTG$Dose˜ f ( i n l a . group (dataLLTG$Time , n=50) ,
model=”rw2 ” , s c a l e . model = TRUE, hyper = l i s t ( prec = l i s t ( p r i o r=”pc . prec ” ,
param=c (1 , 0 . 0 1 ) ) ) ) , data=dataLLTG , fami ly=”gauss ian ” , c o n t r o l . compute=
l i s t ( d i c=TRUE, c o n f i g=TRUE) )
#Plot means
p l o t (modCBZ$summary . random$ ‘ i n l a . group (dataLCBZ | S |Time , n =
5 0 ) ‘ [ , 1 ]∗2 4 0 0 , l og (modCBZ$summary . f i x e d [1 ,1 ]+
modCBZ$summary . random$ ‘ i n l a . group (dataLCBZ | S |Time , n = 5 0 ) ‘ [ , 2 ] ) ,
type=” l ” , lwd=2, ylim=c ( 0 . 5 , 1 . 2 ) , x lab=”Time” , ylab=”log ( Dose )” ,
xl im=c (0 ,2400 ) )
l i n e s (modLTG$summary . random$ ‘ i n l a . group (dataLLTG | S |Time , n = 5 0 ) ‘ [ , 1 ]
∗2400 , l og (modLTG$summary . f i x e d [1 ,1 ]+
modLTG$summary . random$ ‘ i n l a . group (dataLLTG | S |Time , n = 5 0 ) ‘ [ , 2 ] ) ,
l t y =2, lwd=2)
legend ( x=2000 ,y=0.7 , l egend=c (”CBZ” ,”LTG”) , l t y=c ( 1 , 2 ) , lwd=c ( 2 , 2 ) )
#Jo int model
#Pre−work f o r e n t i r e p r e d i c t o r
nL<−nrow ( dataL )
nS<−nrow ( dataS )
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f i x e d . e f f<−data . frame (mu=as . f a c t o r ( c ( rep (1 ,nL ) , rep (1 ,nL ) , rep (2 , nS ) ,
rep (3 , nS ) ) ) ,
ageL=c ( dataL$Age , dataL$Age , rep (0 , nS ) , rep (0 , nS ) ) ,
ageUAE=c ( rep (0 ,nL ) , rep (0 ,nL ) , dataS$Age , rep (0 , nS ) ) ,
ageISC=c ( rep (0 ,nL ) , rep (0 ,nL ) , rep (0 , nS ) , dataS$Age ) ,
treatmentL=as . f a c t o r ( c ( dataL$Treatment , dataL$Treatment , rep (NA, nS ) ,
rep (NA, nS ) ) ) ,
treatmentUAE=as . f a c t o r ( c ( rep (NA, nL ) , rep (NA, nL ) , dataS$Treatment ,
rep (NA, nS ) ) ) ,
treatmentISC=as . f a c t o r ( c ( rep (NA, nL ) , rep (NA, nL ) , rep (NA, nS ) ,
dataS$Treatment ) ) ,
genderL=as . f a c t o r ( c ( dataL$Gender , dataL$Gender , rep (NA, nS ) ,
rep (NA, nS ) ) ) ,
genderUAE=as . f a c t o r ( c ( rep (NA, nL ) , rep (NA, nL ) , dataS$Gender ,
rep (NA, nS ) ) ) ,
genderISC=as . f a c t o r ( c ( rep (NA, nL ) , rep (NA, nL ) , rep (NA, nS ) ,
dataS$Gender ) ) )
random . e f f<− l i s t ( timeL LTG=c ( dataL$InteractionLTG , rep (NA, nL ) ,
rep (NA, nS ) , rep (NA, nS ) ) ,
timeL CBZ=c ( dataL$InteractionCBZ , rep (NA, nL ) , rep (NA, nS ) ,
rep (NA, nS ) ) ,
l inpredL=c ( rep (NA, nL ) , dataL$ID , rep (NA, nS ) , rep (NA, nS ) ) ,
l inpredL2=c ( rep (NA, nL ) , rep (−1 ,nL ) , rep (NA, nS ) , rep (NA, nS ) ) ,
betaUAE=c ( rep (NA, nL ) , rep (NA, nL ) , dataS$ID , rep (NA, nS ) ) ,
betaISC=c ( rep (NA, nL ) , rep (NA, nL ) , rep (NA, nS ) , dataS$ID ) ,
frai ltyUAE=c ( rep (NA, nL ) , rep (NA, nL ) , dataS$ID , rep (NA, nS ) ) ,
f r a i l t y I S C=c ( rep (NA, nL ) , rep (NA, nL ) , rep (NA, nS ) , dataS$ID ) )
jo in tdata<−c ( f i x e d . e f f , random . e f f )
y . long <− c ( dataL$Dose , rep (NA, nL ) , rep (NA, nS ) , rep (NA, nS ) )
y . eta<−c ( rep (NA, nL ) , rep (0 ,nL ) , rep (NA, nS ) , rep (NA, nS ) )
y . survUAE <− i n l a . surv ( time = c ( rep (NA, nL ) , rep (NA, nL ) ,
dataS$Time , rep (NA, nS ) ) ,
event = c ( rep (NA, nL ) , rep (NA, nL ) , dataS$StatusUAE , rep (NA, nS ) ) )
y . survISC <− i n l a . surv ( time = c ( rep (NA, nL ) , rep (NA, nL ) ,
rep (NA, nS ) , dataS$Time ) ,
event = c ( rep (NA, nL ) , rep (NA, nL ) , rep (NA, nS ) , dataS$StatusISC ) )
y . j o i n t<− l i s t ( y . long , y . eta , y . survUAE , y . survISC )
jo intdata$Y=y . j o i n t
#Model f i t
formula . model=Y˜ treatmentL+treatmentUAE+treatmentISC+
f ( i n l a . group ( timeL LTG , n=50) , model=”rw2 ” , s c a l e . model = TRUE, hyper
= l i s t ( prec = l i s t ( p r i o r=”pc . prec ” , param=c (1 , 0 . 01 ) ) ) )+
f ( i n l a . group ( timeL CBZ , n=50) , model=”rw2 ” , s c a l e . model = TRUE, hyper
= l i s t ( prec = l i s t ( p r i o r=”pc . prec ” , param=c (1 , 0 . 01 ) ) ) )+
f ( l inpredL , l inpredL2 , model=” i i d ” , hyper = l i s t ( prec = l i s t ( i n i t i a l = −6,
f i x e d=TRUE) ) ) +
f (betaUAE , copy=”l inpredL ” , hyper = l i s t ( beta = l i s t ( f i x e d = FALSE)))+
f ( betaISC , copy=”l inpredL ” , hyper = l i s t ( beta = l i s t ( f i x e d = FALSE) ) )
Jointmodel= i n l a ( formula . model , f ami ly = c (” gauss ian ” ,” gauss ian ” ,
” we ibu l l su rv ” ,” we ibu l l su rv ”) ,
data = jo in tdata , verbose=TRUE, c o n t r o l . compute=l i s t ( d i c=TRUE) ,
c o n t r o l . f ami ly = l i s t (
l i s t ( ) ,
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l i s t ( hyper = l i s t ( prec = l i s t ( i n i t i a l = 10 , f i x e d=TRUE) ) ) ,
l i s t ( ) ,
l i s t ( )
)
)
summary( Jointmodel )
##Random e f f e c t s only
f i x e d . e f f<−data . frame (mu=as . f a c t o r ( c ( rep (1 ,nL ) , rep (2 , nS ) , rep (3 , nS ) ) ) ,
ageL=c ( dataL$Age , rep (0 , nS ) , rep (0 , nS ) ) ,
ageUAE=c ( rep (0 ,nL ) , dataS$Age , rep (0 , nS ) ) ,
ageISC=c ( rep (0 ,nL ) , rep (0 , nS ) , dataS$Age ) ,
treatmentL=as . f a c t o r ( c ( dataL$Treatment , rep (NA, nS ) , rep (NA, nS ) ) ) ,
treatmentUAE=as . f a c t o r ( c ( rep (NA, nL ) , dataS$Treatment , rep (NA, nS ) ) ) ,
treatmentISC=as . f a c t o r ( c ( rep (NA, nL ) , rep (NA, nS ) , dataS$Treatment ) ) ,
genderL=as . f a c t o r ( c ( dataL$Gender , rep (NA, nS ) , rep (NA, nS ) ) ) ,
genderUAE=as . f a c t o r ( c ( rep (NA, nL ) , dataS$Gender , rep (NA, nS ) ) ) ,
genderISC=as . f a c t o r ( c ( rep (NA, nL ) , rep (NA, nS ) , dataS$Gender ) ) ,
UAETime=c ( rep (0 ,nL ) , dataS$Time , rep (0 , nS ) ) ,
ISCTime=c ( rep (0 ,nL ) , rep (0 , nS ) , dataS$Time ) ,
Ltime=c ( dataL$Time , rep (0 , nS ) , rep (0 , nS ) ) )
random . e f f<− l i s t ( timeL=c ( dataL$Time , rep (NA, nS ) , rep (NA, nS ) ) ,
Lr1=c ( dataL$ID , rep (NA, nS ) , rep (NA, nS ) ) ,
Lr2=c ( dataL$ID , rep (NA, nS ) , rep (NA, nS ) ) ,
UAEr1=c ( rep (NA, nL ) , dataS$ID , rep (NA, nS ) ) ,
UAEr2=c ( rep (NA, nL ) , dataS$ID , rep (NA, nS ) ) ,
ISCr1=c ( rep (NA, nL ) , rep (NA, nS ) , dataS$ID ) ,
ISCr2=c ( rep (NA, nL ) , rep (NA, nS ) , dataS$ID ) ,
frai ltyUAE=c ( rep (NA, nL ) , dataS$ID , rep (NA, nS ) ) ,
f r a i l t y I S C=c ( rep (NA, nL ) , rep (NA, nS ) , dataS$ID ) )
jo in tdata<−c ( f i x e d . e f f , random . e f f )
y . long <− c ( dataL$Dose , rep (NA, nS ) , rep (NA, nS ) )
y . survUAE <− i n l a . surv ( time = c ( rep (NA, nL ) , dataS$Time , rep (NA, nS ) ) ,
event = c ( rep (NA, nL ) , dataS$StatusUAE , rep (NA, nS ) ) )
y . survISC <− i n l a . surv ( time = c ( rep (NA, nL ) , rep (NA, nS ) , dataS$Time ) ,
event = c ( rep (NA, nL ) , rep (NA, nS ) , dataS$StatusISC ) )
y . j o i n t<− l i s t ( y . long , y . survUAE , y . survISC )
jo intdata$Y=y . j o i n t
#Model f i t
formula . model=Y˜ treatmentL+treatmentUAE+treatmentISC+
f ( Lr1 , model=”i i d 2 d ” ,n=2∗(nL+nS+nS ) ) +
f ( Lr2 , Ltime , copy=”Lr1 ” , f i x e d=TRUE)+
f (UAEr1 , copy=”Lr1 ” , f i x e d=FALSE)+ f (UAEr2 ,UAETime, copy=”UAEr1” , f i x e d=FALSE)+
f ( ISCr1 , copy=”Lr1 ” , f i x e d=FALSE)+ f ( ISCr2 , ISCTime , copy=”ISCr1 ” , f i x e d=FALSE)
Jointmodel= i n l a ( formula . model , f ami ly = c (” gauss ian ” ,” we ibu l l su rv ” ,
” we ibu l l su rv ”) ,
data = jo in tdata , verbose=TRUE, c o n t r o l . compute=l i s t ( d i c=TRUE) )
summary( Jointmodel )
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